A comparison of the ocular hypotensive effect of 0.025% bromocriptine and 0.25% timolol eye drops in normal human volunteers.

Al-Sereiti, M. R.; Coakes, Roger L.; O'sullivan, D. P. D.; Turner, Paul

doi:10.1111/j.1365-2125.1989.tb03525.x

Cited by 11 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zimmerman and Kaufman proposed that unilateral timolol application, shown in several investigations to reduce IOP in the fellow eye, could do so via systemic absorption and delivery. 1–4, 7–9, 31, 32 …”

Section: Discussionmentioning

confidence: 99%

The Effect of Trabeculectomy on Intraocular Pressure of the Untreated Fellow Eye in the Collaborative Initial Glaucoma Treatment Study

et al. 2010

View full text Add to dashboard Cite

Purpose To describe the intraocular pressure (IOP) of the untreated fellow eye following unilateral trabeculectomy in the Collaborative Initial Glaucoma Treatment Study (CIGTS). Design Data collected from a prospective, multicenter, randomized clinical trial Participants Three hundred patients with newly diagnosed open-angle glaucoma enrolled at 14 centers in the United States who were randomized to initial trabeculectomy. Methods After baseline evaluation and randomization to initial trabeculectomy in the study eye, patients were evaluated at 3 and 6 months, and at 6-month intervals thereafter. The IOP was measured by Goldmann applanation tonometry. All eyes included in the analysis were untreated fellow eyes, and the data were censored for potential IOP lowering events in the fellow eye including trabeculectomy, argon laser trabeculoplasty or cataract extraction. Predictive factors for IOP response in the fellow eye to initial trabeculectomy in the study eye were analyzed using a linear mixed model. Main Outcome Measure IOP in the untreated fellow eye during follow up. Results While the IOP in the fellow eye was lower than baseline at 3, 6, 12, 18 and 24 months after trabeculectomy in the study eye, this decrease was statistically significant only at month 12 (mean decrease from baseline, 0.73±3.37 mm Hg; P=0.0134). Predictive associations with higher IOP in the fellow eye during follow-up included higher baseline IOP (P<0.0001), lower level of education (P=0.0129), time (p=0.0005) and the presence of other vascular disease (p=0.0069). Patients who ultimately required fellow eye trabeculectomy (p<0.0001) or argon laser trabeculoplasty (p<0.0001) but not cataract extraction (p=0.4597) in the fellow eye had lower IOPs during follow-up after these procedures. Conclusion There was no evidence of a substantial effect of trabeculectomy on the untreated fellow eye IOP during follow up. Trabeculectomy does not appear to decrease the mean IOP of the fellow eye, as suggested by some previous studies.

show abstract

Section: Discussionmentioning

confidence: 99%

The Effect of Trabeculectomy on Intraocular Pressure of the Untreated Fellow Eye in the Collaborative Initial Glaucoma Treatment Study

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Bromocriptine, which is marketed as its mesylate salt form, is known for its dopaminergic action [ 37 , 38 ] and its ability to decrease IOP upon local administration. This effect was firstly described in rabbit eyes and further supported by the evidence of its efficacy to reduce IOP in humans upon oral administration.…”

Section: Role Of Ergot Alkaloids In Reducing Intraocular Pressurementioning

confidence: 99%

Natural Ergot Alkaloids in Ocular Pharmacotherapy: Known Molecules for Novel Nanoparticle-Based Delivery Systems

et al. 2020

View full text Add to dashboard Cite

Several pharmacological properties are attributed to ergot alkaloids as a result of their antibacterial, antiproliferative, and antioxidant effects. Although known for their biomedical applications (e.g., for the treatment of glaucoma), most ergot alkaloids exhibit high toxicological risk and may even be lethal to humans and animals. Their pharmacological profile results from the structural similarity between lysergic acid-derived compounds and noradrenalin, dopamine, and serotonin neurotransmitters. To reduce their toxicological risk, while increasing their bioavailability, improved delivery systems were proposed. This review discusses the safety aspects of using ergot alkaloids in ocular pharmacology and proposes the development of lipid and polymeric nanoparticles for the topical administration of these drugs to enhance their therapeutic efficacy for the treatment of glaucoma.

show abstract

Effect of Intravenous Fenoldopam on Intraocular Pressure in Ocular Hypertension

Everitt

Boike

Piltz-Seymour

et al. 1997

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Intravenous fenoldopam, a selective dopamine-1 receptor agonist, was compared with placebo in this randomized, double-blind, two-period crossover study to evaluate its effects on intraocular pressure, aqueous dynamics, and macular blood flow in patients with elevated intraocular pressure or primary open-angle glaucoma. Doses of fenoldopam were titrated up to a maximum of 0.5 microgram/kg/min. Intraocular pressure, measured by pneumotonometry, was the primary outcome variable. Other outcomes included macular blood flow assessed by blue field examination, visual field examined by automated perimetry, aqueous outflow facility measured by tonography, and aqueous humor production determined by fluorophotometry. During infusions of fenoldopam, intraocular pressure increased from a mean baseline level of 29.2 mmHg to a mean maximum level of 35.7 mmHg. During the placebo infusions, pressure increased from a mean baseline of 28.4 mmHg to a mean of 29.0 mmHg at the time point that corresponded to the mean maximum intraocular pressure on the day intravenous fenoldopam was administered, to yield a mean difference in pressure between study days of 6.7 mmHg (P < 0.05). There were no apparent changes in macular blood flow, visual fields, or production or outflow of aqueous humor associated with fenoldopam infusion. The increase in intraocular pressure seen in this population of patients with ocular hypertension during infusions of fenoldopam is consistent with fenoldopam-associated increases in intraocular pressure reported in previous studies of healthy volunteers and of patients with accelerated systemic hypertension. These results further suggest that dopamine-1 receptors play a role in the regulation of intraocular pressure.

show abstract

A comparison of the ocular hypotensive effect of 0.025% bromocriptine and 0.25% timolol eye drops in normal human volunteers.

Cited by 11 publications

References 18 publications

The Effect of Trabeculectomy on Intraocular Pressure of the Untreated Fellow Eye in the Collaborative Initial Glaucoma Treatment Study

The Effect of Trabeculectomy on Intraocular Pressure of the Untreated Fellow Eye in the Collaborative Initial Glaucoma Treatment Study

Natural Ergot Alkaloids in Ocular Pharmacotherapy: Known Molecules for Novel Nanoparticle-Based Delivery Systems

Effect of Intravenous Fenoldopam on Intraocular Pressure in Ocular Hypertension

Contact Info

Product

Resources

About